A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer
Status:
Active, not recruiting
Trial end date:
2024-11-30
Target enrollment:
Participant gender:
Summary
This research study is studying a drug as a possible treatment for p53 mutant metastatic
colorectal cancer.
The drug involved in this study is:
-Lamivudine